Sustained response rate, organ response, and response in multiple organs among patients who responded to ibrutinib
| . | No. of responders . | Sustained response rate n (%) . |
|---|---|---|
| Sustained response of ≥20 wk | 28 | 20 (71) |
| Organ | No. of responders with organ involvement at baseline | Best ORR, n (%) |
| Skin | 24 | 21 (88) |
| Mouth | 24 | 21 (88) |
| Gastrointestinal | 11 | 10 (91) |
| Organs showing response | No. of patients with ≥2 involved organs at baseline among responders | Best ORR, n (%) |
| ≥2 organs | 25 | 20 (80) |
| . | No. of responders . | Sustained response rate n (%) . |
|---|---|---|
| Sustained response of ≥20 wk | 28 | 20 (71) |
| Organ | No. of responders with organ involvement at baseline | Best ORR, n (%) |
| Skin | 24 | 21 (88) |
| Mouth | 24 | 21 (88) |
| Gastrointestinal | 11 | 10 (91) |
| Organs showing response | No. of patients with ≥2 involved organs at baseline among responders | Best ORR, n (%) |
| ≥2 organs | 25 | 20 (80) |